Suppr超能文献

利用外周血造血祖细胞计数代替部分CD34细胞计数的算法能够预测外周血干细胞采集成功,且能大幅节省时间和成本。

Algorithms utilizing peripheral blood hematopoietic progenitor cell counts in lieu of some CD34 cell counts predict successful peripheral blood stem cell collections with substantial time and cost savings.

作者信息

Steussy B W, Capper M, Krasowski M D, Rosenthal N S, Schlueter A J

机构信息

Department of Pathology, University of Iowa, Iowa City, IA, USA.

出版信息

ISBT Sci Ser. 2016 Dec;11(3):153-162. doi: 10.1111/voxs.12289. Epub 2016 Oct 5.

Abstract

BACKGROUND AND OBJECTIVES

Hematopoietic progenitor cell (HPC) counts from Sysmex hematology analyzers have been shown to correlate with peripheral blood (PB) CD34+ cell counts by flow cytometry. Algorithms utilizing HPC counts to guide stem cell collections have been proposed but rarely tested. This study describes the development and validation of algorithms utilizing HPC and PB CD34+cell counts to predict adequate peripheral blood stem cell (PBSC) collections for chemomobilized and cytokine-mobilized individuals.

MATERIALS AND METHODS

Utilizing a test set of 83 PB samples from chemomobilized or cytokine-mobilized PBSC collection patients, PB CD34+ counts were correlated with HPC counts and a receiver operating characteristic curve was constructed. Cut-offs of ≤0.5 HPC/μl and ≥7 HPC/μl were established to maximize sensitivity and specificity for using HPC to predict PB CD34+ ≥ 10 cells/μl. These cut-offs were subsequently validated using a separate prospective validation set of 88 HPC/CD34+ cell sample pairs.

RESULTS

Using the algorithms, all patients in the prospective validation data set achieved adequate collections of ≥1 × 10 CD34 cells/kg, and a 67% reduction in the number of CD34 cell counts performed was achieved. This lead to a direct cost savings of at least $18,700 USD over a 21-month period (88% reduction in direct costs).

CONCLUSION

Use of the algorithms provides significant time and cost savings for the laboratory while accurately predicting (i) timing of PBSC collections to obtain adequate CD34 product yields for chemomobilized patients and (ii) when to administer plerixafor to cytokine-mobilized patients to improve the likelihood of achieving adequate collections.

摘要

背景与目的

Sysmex血液分析仪检测的造血祖细胞(HPC)计数已被证明与流式细胞术检测的外周血(PB)CD34+细胞计数相关。已有人提出利用HPC计数来指导干细胞采集的算法,但很少进行测试。本研究描述了利用HPC和PB CD34+细胞计数来预测化疗动员和细胞因子动员个体外周血干细胞(PBSC)采集量是否充足的算法的开发与验证。

材料与方法

利用来自化疗动员或细胞因子动员的PBSC采集患者的83份PB样本组成的测试集,将PB CD34+计数与HPC计数进行相关性分析,并构建受试者工作特征曲线。确定≤0.5 HPC/μl和≥7 HPC/μl的临界值,以最大化使用HPC预测PB CD34+≥10细胞/μl的敏感性和特异性。随后使用由88对HPC/CD34+细胞样本组成的独立前瞻性验证集对这些临界值进行验证。

结果

使用这些算法,前瞻性验证数据集中的所有患者均获得了≥1×10 CD34细胞/kg的充足采集量,并且CD34细胞计数检测次数减少了67%。这在21个月的时间内直接节省了至少18,700美元(直接成本降低了88%)。

结论

使用这些算法可为实验室显著节省时间和成本,同时准确预测:(i)PBSC采集的时间,以获得化疗动员患者足够的CD34产物产量;(ii)何时向细胞因子动员患者施用普乐沙福,以提高获得充足采集量的可能性。

相似文献

引用本文的文献

本文引用的文献

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验